Sucampo Pharmaceuticals, Inc. ("Sucampo") (NASDAQ: SCMP), a global
pharmaceutical company, today announced that it will host a meeting to
discuss the recent opioid-induced constipation (OIC) indication approval
for its flagship product, AMITIZA, on May 20, 2013, from 9:00 to 10:30AM
ET in Orlando, FL. Members of Sucampo's management team and two key
outside experts will provide a market update, overview of the scientific
data, and clinical perspectives relevant to OIC.
If you would like to attend the event in Orlando, please RSVP to email@example.com
as space is limited.
Those interested in accessing the live audio webcast of the
teleconference may do so at http://investor.sucampo.com/phoenix.zhtml?c=201197&p=irol-calendar
and should log on 10 to 15 minutes before the meeting begins in order to
download any software required. Presentation slides will be available
via the webcast links. A replay of the webcast will also be available on
the Company's website for several days after the live event.
Alternatively, participants may dial 866-515-2907 (domestic) or
617-399-5121 (international) and use passcode 24996242. A replay of the
teleconference will be available by dialing 888-286-8010 (domestic) or
617-801-6888, passcode 41707791, approximately two hours after the
teleconference concludes. The archive of the teleconference will remain
available for 30 days.
About Opioid Induced Constipation (OIC)
OIC is a common adverse effect of chronic opioid use. Binding of opioids
to peripheral opioid receptors in the gastrointestinal tract results in
absorption of electrolytes, such as chloride, and subsequent reduction
in small intestinal fluid. In addition, activation of enteric opioid
receptors results in abnormal GI motility. Together, these processes
result in OIC, which is characterized by infrequent and incomplete
evacuation of stool, hard stool consistency, and straining associated
with bowel movements.
About lubiprostone (AMITIZA®)
AMITIZA (lubiprostone) is a prostone, a locally acting chloride channel
activator, indicated for the treatment of chronic idiopathic
constipation (CIC) in adults and OIC in adults with chronic, non-cancer
pain (24 mcg twice daily) and for irritable bowel syndrome with
constipation (8 mcg twice daily) in women 18 years of age and older in
the United States. In Japan, lubiprostone (24 mcg twice daily) is
indicated for the treatment of chronic constipation (excluding
constipation caused by organic diseases). In Switzerland, lubiprostone
(24 mcg twice daily) is indicated for the treatment of CIC. In the U.K.,
lubiprostone (24 mcg twice daily) is indicated for the treatment of CIC
and associated symptoms in adults.
About Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc. is a global pharmaceutical company focused
on innovative research, discovery, development and commercialization of
proprietary drugs based on prostones. The therapeutic potential of
prostones was first discovered by Ryuji Ueno, M.D., Ph.D., Ph.D.,
Sucampo's Chairman, Chief Executive Officer, Chief Scientific Officer,
and co-founder. Prostones, naturally occurring fatty acid metabolites
that have emerged as promising compounds with unique physiological
activities, can be targeted for the treatment of unmet or underserved
medical needs. For more information, please visit www.sucampo.com.
AMITIZA is a registered trademark of Sucampo AG. The Sucampo logo and
the tagline, The Science of Innovation, are registered trademarks of
Sucampo Forward-Looking Statement
This press release contains "forward-looking statements" as that term is
defined in the Private Securities Litigation Reform Act of 1995. These
statements are based on management's current expectations and involve
risks and uncertainties, which may cause results to differ materially
from those set forth in the statements. The forward-looking statements
may include statements regarding product development, product potential,
future financial and operating results, and other statements that are
not historical facts. The following factors, among others, could cause
actual results to differ from those set forth in the forward-looking
statements: the impact of pharmaceutical industry regulation and health
care legislation; Sucampo's ability to accurately predict future market
conditions; dependence on the effectiveness of Sucampo's patents and
other protections for innovative products; the risk of new and changing
regulation and health policies in the U.S. and internationally and the
exposure to litigation and/or regulatory actions.
No forward-looking statement can be guaranteed and actual results may
differ materially from those projected. Sucampo undertakes no obligation
to publicly update any forward-looking statement, whether as a result of
new information, future events, or otherwise. Forward-looking statements
in this presentation should be evaluated together with the many
uncertainties that affect Sucampo's business, particularly those
mentioned in the risk factors and cautionary statements in Sucampo's
most recent Form 8-K and 10-K, which Sucampo incorporates by reference.
Sucampo Pharmaceuticals, Inc.
Silvia Taylor, 1-240-223-3718